arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BRAINSTORM CELL THERAPEUTICS INC.

BCLI
Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
100 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
90
Health
Excellent
Bullish
auto_awesome

Analytical Summary

BRAINSTORM CELL THERAPEUTICS INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC 14.7%
FCF / Share $-0.12
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.12
info Valuation on last close.

100-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-2.13M
↑ +25.7%
FCF / Share Free cash flow per share
$-0.12
↑ +53.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health
100
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 26 years · 100 quarters